Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 10/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.98 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.98 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.98 |
| ▸ | OGT | O15294 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396726 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL29441461 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL12377962 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL15433957 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL29397191 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL23344493 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL14281873 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL16138527 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL20718791 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL19315974 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TEGA THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | claimed |
| WO-2026101155-A1 | COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS TARGETING GLYCOSYLATION | 서울대학교산학협력단 | 2026-05-15 | — | — | WO | claimed |
| CN-121825925-B | Beta 1, 4-galactosyltransferase Habeta 4GalT-S233P and application thereof in synthesis of LNnT | 中国海洋大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | claimed |
| US-20250388948-A1 | CELL-FREE ENZYMATIC METHOD FOR PREPARATION OF N-GLYCANS | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| US-20250382649-A1 | CELLS WITH TRI-, TETRA- OR PENTASACCHARIDE IMPORTERS USEFUL IN OLIGOSACCHARIDE PRODUCTION | DSM IP ASSETS BV (NL) | 2025-12-18 | — | — | US | claimed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | claimed |
| WO-2025206361-A1 | GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING SUGAR | キリンホールディングス株式会社 | 2025-10-02 | — | — | WO | claimed |
| CN-114207108-A | Genetically modified host cells producing glycosylated cannabinoids | 奥克塔林生物制剂公司 | 2022-03-18 | — | — | CN | claimed |
| CN-114137213-A | Method for in vitro detection of OGT enzyme activity | 无锡麦迪科思生物科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | claimed |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-02 | — | — | US | claimed |
| US-20050266523-A1 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-12-01 | — | — | US | claimed |
| US-6884604-B2 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-26 | — | — | US | claimed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | claimed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | claimed |
| WO-2002079150-A2 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | P2RY14 2873/4885P2RY6 2879/4885P2RY2 3553/4885 |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TPST2, CSGALNACT1, B4GALT1 | P2RY14 586/4885P2RY6 1021/4885P2RY2 744/4885 |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | P2RY14 479/4885P2RY6 309/4885P2RY2 689/4885 |
| US-20250388948-A1 | CELL-FREE ENZYMATIC METHOD FOR PREPARATION OF N-GLYCANS | MAN2A1, ENGASE, MAN2B1 | P2RY14 4526/4885P2RY6 4516/4885P2RY2 4385/4885 |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | PNP, NUDT14, NUDT5 | P2RY14 424/4885P2RY6 324/4885P2RY2 678/4885 |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | P2RY14 1614/4885P2RY6 1568/4885P2RY2 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.